Refractory hypertension in a patient with resistant disease
A 61-year-old man with obesity (BMI 34), type 2 diabetes, and stage 3a CKD has office BP 158/96 despite lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. Home readings average 150/94. He reports loud snoring and daytime sleepiness. Labs: potassium 3.4, sodium 139, creatinine 1.6 (baseline 1.5), eGFR 42, glucose 148, HbA1c 8.1%. He takes ibuprofen most days for knee pain and uses a decongestant spray nightly. He is adherent by pill count.
1. Before labeling this resistant hypertension, what reversible contributors must be addressed, and how does each map to his data?
Read the worked answer
Several factors can produce apparent resistance and should be corrected first:
- Medication-induced elevation - NSAIDs (ibuprofen) cause sodium/water retention and blunt antihypertensives; decongestants (pseudoephedrine/phenylephrine) are sympathomimetics. Both are daily here and should be stopped or substituted.
- Volume overload / inadequate diuretic effect - CKD and a high-sodium diet can overcome chlorthalidone; consider dietary sodium review and possibly a loop diuretic if eGFR is low enough that thiazide-like efficacy is limited.
- Obstructive sleep apnea - snoring plus daytime sleepiness; untreated OSA is a common cause of resistant hypertension and should prompt sleep study.
- Hypokalemia (3.4) - on an ACE inhibitor plus diuretic, this is suspicious for primary aldosteronism; screen with aldosterone/renin ratio (after correcting potassium, and noting that ACE inhibitors and diuretics affect the ratio).
- CKD and diabetes - contribute to hypertension and complicate drug choice.
- Measurement technique - confirm proper cuff size and technique; home readings support true elevation.
Only after these are addressed is 'resistant hypertension' a firm label.
2. Assuming contributors are optimized and BP remains elevated, how would you adjust his regimen, and what monitoring is required?
Read the worked answer
With ACE inhibitor + calcium channel blocker + thiazide-like diuretic already maximal, the next step is add spironolactone (typically 12.5–25 mg) as the evidence-based fourth agent for resistant hypertension - but only after checking potassium and renal function:
- His K is 3.4 and eGFR 42; spironolactone raises potassium and can worsen renal function, so recheck K and creatinine within 1–2 weeks and after each dose change. If K is low now, correcting it first also improves aldosterone screening.
- If spironolactone is contraindicated or hyperkalemia develops, alternatives include a beta-blocker, hydralazine, or central alpha-agonist (clonidine) - but these have more side effects and less outcome evidence in this setting.
- Consider whether a loop diuretic is more appropriate than chlorthalidone given CKD stage 3a and volume status.
- Reassess diabetes control (HbA1c 8.1%) and use agents with cardiovascular/renal benefit (SGLT2 inhibitor, GLP-1 receptor agonist) - these also modestly lower BP and slow CKD progression.
- Reinforce sodium restriction, weight loss, and treat OSA if confirmed.
Recheck BP with home monitoring and labs after each change.
3. His potassium comes back low and the aldosterone/renin ratio is elevated. Why does this matter beyond blood pressure control, and what is the management implication?
Read the worked answer
An elevated aldosterone/renin ratio with hypokalemia suggests primary aldosteronism, which matters for several reasons:
- It is a specifically treatable cause - either surgically (unilateral adenoma, via adrenal vein sampling and laparoscopic adrenalectomy) or medically (bilateral hyperplasia, with a mineralocorticoid receptor antagonist).
- Cardiovascular risk - aldosterone excess causes myocardial fibrosis, arrhythmia, and stroke risk beyond what BP alone predicts; treating it improves outcomes.
- Drug interactions - ACE inhibitors and diuretics alter the ratio; interpretation requires care, and confirmatory testing (saline suppression, captopril challenge) is usually needed before committing to adrenal imaging.
- Potassium correction - hypokalemia both confounds and is caused by the condition; correcting it before repeat testing improves accuracy.
The implication: do not simply add another antihypertensive and move on. Pursue confirmatory testing and, if confirmed, subtype the disease, because the management pathway (surgery vs MRA) differs and both improve long-term risk.